Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile
- DOI
- 10.1182/bloodadvances.2023011858
- Published
- 2024-04-26
- Container
- Blood Advances
- Publisher
- American Society of Hematology
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1182/bloodadvances.2023011858,
title = {Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile},
author = {Zhihong Zeng and Annelies Roobrouck and Geert Deschamps and Helene Bonnevaux and Stephane Guerif and Veronique De Brabandere and Céline Amara and Eline Dejonckheere and Angela Virone-Oddos and Marielle Chiron and Marina Konopleva and Melissa Dullaers},
year = {2024},
journal = {Blood Advances},
doi = {10.1182/bloodadvances.2023011858},
url = {https://doi.org/10.1182/bloodadvances.2023011858}
}RIS
TY - JOUR TI - Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile AU - Zhihong Zeng AU - Annelies Roobrouck AU - Geert Deschamps AU - Helene Bonnevaux AU - Stephane Guerif AU - Veronique De Brabandere AU - Céline Amara AU - Eline Dejonckheere AU - Angela Virone-Oddos AU - Marielle Chiron AU - Marina Konopleva AU - Melissa Dullaers PY - 2024 JO - Blood Advances DO - 10.1182/bloodadvances.2023011858 UR - https://doi.org/10.1182/bloodadvances.2023011858 ER -
APA
Zeng, Z., Roobrouck, A., Deschamps, G., Bonnevaux, H., Guerif, S., Brabandere, V. D., Amara, C., Dejonckheere, E., Virone-Oddos, A., Chiron, M., Konopleva, M., & Dullaers, M. (2024). Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile. Blood Advances. https://doi.org/10.1182/bloodadvances.2023011858
Source records
- crossref · retrieved 2026-09-26T22:13:27.627Z